Novarits: breakthrough therapy designation to capmatinib for NSCLC, EC approval for Lucentis in preterm infants with ROP

The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis.

Read more